Drug Trial Radar · NCT06388187
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
Last checked: Nov 20, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
Jun 24, 2024
Primary completion
Apr 22, 2026
Study completion Apr 22, 2026
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Apr 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get CagriSema or dummy medicine and which treatment participant get is decided by chance. The study will last for about 1½ years for each participant.
Conditions
- Obesity
Interventions
CagrilintideDrug
Participants will receive once-weekly cagrilintide subcutaneously.
SemaglutideDrug
Participants will receive once-weekly semaglutide subcutaneously.
PlaceboDrug
Participants will receive once-weekly placebo matched to cagrilintide and semaglutide subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative change in body weightTime frame: From baseline (week 0) to end of treatment (week 68)
- Achievement of ≥5% weight reductionTime frame: From baseline (week 0) to end of treatment (week 68)
Locations
25 sites in 5 countries. Site status is shown where the registry gives one.
Aurora FDRC Inc.
Costa Mesa, California
Clinical Trial Res Assoc,Inc
Plantation, Florida
Midwest Inst For Clin Res
Indianapolis, Indiana
Accellacare
Wilmington, North Carolina
Velocity Clinical Res-Dallas
Dallas, Texas
Washington Cntr Weight Mgmt
Arlington, Virginia
Capital Clin Res Ctr,LLC
Olympia, Washington
Ocean West Research Clinic
Surrey, British Columbia, Canada
Nova Scotia Health Authority
Halifax, Nova Scotia, Canada
Wharton Medical Clinic Clinical Trials (Hamilton)
Hamilton, Ontario, Canada
Hospices Civils de Lyon-Hopital Lyon Sud-1
Pierre-Bénite, France
Hospices Civils de Lyon-Hopital Lyon Sud
Pierre-Bénite, France
Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec
Saint-Herblain, France
Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil
Toulouse, France
InnoDiab Forschung GmbH
Essen, Germany
Wendisch - Dahl Hamburg - DZHW
Hamburg, Germany
AmBeNet GmbH
Leipzig, Germany
Institut für Diabetesforschung GmbH Münster - Dr. med. Rose
Münster, Germany
Forschungszentrum Ruhr KliFoCenter GmbH, Kahrmann
Witten, Germany
The Health Centre
Bradford on Avon, United Kingdom
Southmead Hospital
Bristol, United Kingdom
Addenbrooke's Hospital_Cambridge
Cambridge, United Kingdom
University Hospital Coventry - WISDEM Centre
Coventry, United Kingdom
Staploe Medical Centre
Soham, United Kingdom
Joint Clinical Research Facility - Swansea
Swansea, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.